Dr. Kimberly Ann Moore, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 174 Dapplegray Rd, Bell Canyon, CA 91307 Phone: 818-481-6940 |
News Archive
Esperion Therapeutics, a privately held biotechnology company working to discover, develop and commercialize treatments for cardiovascular and metabolic diseases, today announced that it has initiated a Phase 2 clinical study for ETC-1002, the company's lead product candidate.
The Broad Medical Research Program, which funds innovative early-stage research into inflammatory bowel disease, will merge with the Crohn's & Colitis Foundation of America, the two organizations announced today.
Illumina today announced that on August 1, 2011, its Board of Directors authorized the Company to repurchase, on a discretionary basis, up to $100 million of its outstanding common shares in the open market or in privately negotiated transactions, subject to market conditions and other factors. The previous discretionary $100 million share repurchase program authorized in July 2010 was completed this week.
Korea Brain Research Institute (KBRI, President Suh Pann-ghill) announced that the research team led by Dr. Jae-Yeol Joo discovered new cryptic splice variants and SNVs in PLCg1 gene of AD-specific models for the first time using Splice-AI.
Psychiatrists are doing a "modest" job of monitoring for weight gain, diabetes and other metabolic problems that may result from use of the newer antipsychotics for schizophrenia, researchers say.
› Verified 7 days ago